| Line 299: | Line 299: | ||
===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== | ===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== | ||
*This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. | *This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. | ||
===2019: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876707/ E-Cigarettes and Smoking Cessation in Smokers With Chronic Conditions]=== | |||
*At a population level, e-cigarette use by smokers with chronic medical conditions is associated with more quitting activity and smoking abstinence. | |||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876707/pdf/nihms-1539531.pdf PDF Version] | |||
<br> | <br> | ||
edits